CD19 and acute lymphoblastic leukemia: A phase I pediatric trial (PALL, NCT02808442) for high-risk R/R CD19-positive B-ALL and a phase I dose-escalation adult trial (CALM, NCT02746952) for patients with R/R B-ALL are underway.